All In Biotech

Drug Trial Radar · NCT01406444

IGF-1 and Bone Loss in Women With Anorexia Nervosa

Last checked: Nov 20, 2026Latest source record: Jul 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 148 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

148

Actual

Start

Oct 2011

Primary completion

May 2019

Study completion May 2019

Sponsor

Lead sponsor
Massachusetts General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 1, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Anorexia nervosa is an eating disorder that can cause thinning of the bones (a decrease in bone density). A significant decrease in bone density is called osteopenia or osteoporosis. Sometimes the loss of bone density can be severe enough to cause breaks and fractures of the bones. It is not known what causes the bones to thin in anorexia nervosa. Women who have this condition often have thin or weak bones that are more likely to break. They also have very low levels of a chemical called IGF-1 in their body. This chemical is very important for increasing bone growth in puberty and for maintaining healthy adult bones. The investigators would like to find out if giving rhIGF-1 followed by risedronate or risedronate alone can lead to an increase in bone formation, bone density, and bone strength in women with anorexia nervosa.

Conditions

  • Anorexia Nervosa
  • Osteopenia
  • Osteoporosis

Interventions

  • rhIGF-1Drug

    Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.

  • RisedronateDrug

    Risedronate 35mg PO one time weekly

  • PlaceboDrug

    Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Postero-anterior Spine Bone Mineral Density by DXATime frame: 12 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.